Live Breaking News & Updates on Analysis Now Expected

Stay updated with breaking news from Analysis now expected. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

G1 Therapeutics Provides First Quarter 2023 Financial Results and Operational Highlights

- Drove 18% Quarterly Net Revenue Growth of COSELA® Over the Fourth Quarter of 2022; Grew Quarterly Vial Volume by 21% Over Prior Quarter - - Provided Updated Timing for Interim Overall Survival. | May 3, 2023 ....

United States , Jack Bailey , Johnw Umstead , Wedbush Pacgrow , Sacituzumab Govitecan Hziy , Raymond James , Investor Relations Corporate Communications , Exchange Commission , European Society For Medical Oncology , American Society Of Clinical Oncology , Therapeutics Inc , Research Triangle Park , Needham Company , Drug Administration On , Quarterly Net Revenue Growth , Fourth Quarter , Grew Quarterly Vial Volume , Over Prior Quarter , Updated Timing , Interim Overall Survival , Pivotal Phase , Metastatic Triple Negative Breast Cancer , Analysis Now Expected , First Quarter , Antibody Drug Conjugate , Additional Results ,